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ABSTRACT		Opioid	drugs	prescribed	legally	have	a	great	potential	for	both	benefit	and	harm.			The	present	study	examines	the	potential	impact	of	regulatory	changes	on	opioid	prescribing	and	use	as	well	as	differences	in	opioid	use	between	men	and	women	and	among	different	age	groups.			The	Utah	All	Payer	Claims	Database	(APCD)	includes	data	that	illuminate	the	effect	of	proposed	changes	to	opioid	prescribing	guidelines.	The	data	were	analyzed	in	a	cross-sectional	study,	with	a	study	population	of	persons	who	were	dispensed	opioids	in	Utah	between	2011	and	2013.	Between	21%	and	44%	of	prescriptions	would	likely	generate	increased	demands	on	provider	time	and	other	resources	under	new	guidelines.		Women	and	older	Utahns	are	dispensed	disproportionately	large	numbers	of	opioids.		Men	and	women	receive	similar	quantities	of	specific	opioids,	suggesting	providers	do	not	consider	the	impact	of	sex	on	opioid	use.		Review	of	the	APCD	data	suggests	possible	improvements	in	data	quality.	In	a	separate	analysis,	data	from	the	Utah	National	Violent	Death	Reporting	System	(NVDRS)	data	were	examined	in	a	retrospective	cohort	study	of	decedents	whose	deaths	involved	prescription	opioids.		Deaths	were	analyzed	by	sex,	by	age	group,	and	by	number	of	causes	of	death	recorded.
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MED	Buprenorphine	 8937	(1.3)	 7724	(2.2)	 6365	(2.0)	 6178	(3.2)	Codeine	 76	(0.0)	 10	(0.0)	 9	(0.0)	 0	(0.0)	
Fentanyl	 28	146	(4.1)	 16	276	(4.6)	 12	186	(3.8)	 6660	(3.4)	
Hydrocodone	 198	491	(28.9)	 51	903	(14.6)	 36	020	(11.1)	 18	345	(9.4)	
Hydromorphone	 13	319	(1.9)	 9928	(2.8)	 8753	(2.7)	 4970	(2.6)	Meperidine	 909	(0.1)	 176	(0.1)	 133	(0.04)	 91	(0.05)	
Methadone	 20	345	(3.0)	 17	313	(4.9)	 17	271	(5.3)	 12	789	(6.6)	
Morphine	 54	968	(8.0)	 37	972	(10.7)	 37	434	(11.5)	 24	305	(12.5)	
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Obtained	for	self	 13	(26.0)	 1373	(54.7)	 1212	(60.9)	 48	(50.5)	 2646	(57.0)	Not	obtained	for	self	
37	(74.0)	 1139	(45.3)	 777	(39.1)	 47	(49.5)	 2000	(43.1)	
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